Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APOPNASDAQ:CYTXOTCMKTS:ECIANASDAQ:LENSNASDAQ:NVIV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPOPCellect Biotechnology$13.17+0.4%$11.51$6.64▼$35.52$12.87M1.87479,845 shs17,400 shsCYTXCytori Therapeutics$1.60-1.8%$0.20$0.20▼$0.75$35.46M1.96915,302 shs8,544 shsECIAEncision$0.44$0.54$0.25▼$0.75$5.22M0.37591 shsN/ALENSPresbia$0.15$0.23▼$5.50$258K2.57122,366 shsN/ANVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPOPCellect Biotechnology0.00%0.00%0.00%0.00%0.00%CYTXCytori Therapeutics0.00%-9.35%-13.98%-16.32%+607.34%ECIAEncision0.00%-37.14%-12.00%-4.35%+12.82%LENSPresbia0.00%0.00%0.00%0.00%0.00%NVIVInVivo Therapeutics0.00%0.00%0.00%-53.25%-76.24%These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPOPCellect BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/ACYTXCytori TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AECIAEncisionN/AN/AN/AN/AN/AN/AN/AN/ALENSPresbiaN/AN/AN/AN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPOPCellect BiotechnologyN/AN/AN/AN/ACYTXCytori TherapeuticsN/AN/AN/AN/AECIAEncisionN/AN/AN/AN/ALENSPresbiaN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPOPCellect BiotechnologyN/AN/AN/AN/A$4.77 per shareN/ACYTXCytori Therapeutics$3.67M9.66N/AN/A$0.35 per share4.57ECIAEncision$7.35M0.71N/AN/A$0.21 per share2.10LENSPresbia$20K0.00N/AN/A$0.09 per share0.00NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPOPCellect Biotechnology-$5.62MN/A0.00∞N/AN/AN/AN/AN/ACYTXCytori Therapeutics-$12.63MN/A0.00∞N/A-242.60%-272.70%-56.23%N/AECIAEncision-$320K-$0.04N/A∞N/A-6.51%-18.97%-10.50%6/20/2024 (Estimated)LENSPresbia-$8.41MN/A0.00N/AN/A-36,604.35%-414.02%-195.56%N/ANVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ALatest NVIV, LENS, APOP, CYTX, and ECIA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/14/2024Q3 2024ECIAEncisionN/A-$0.02-$0.02-$0.02N/A$1.58 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPOPCellect BiotechnologyN/AN/AN/AN/AN/ACYTXCytori TherapeuticsN/AN/AN/AN/AN/AECIAEncisionN/AN/AN/AN/AN/ALENSPresbiaN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPOPCellect BiotechnologyN/A3.013.01CYTXCytori Therapeutics0.390.460.30ECIAEncision0.112.551.08LENSPresbia1.242.882.82NVIVInVivo TherapeuticsN/A14.3014.30OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPOPCellect Biotechnology4.84%CYTXCytori Therapeutics2.62%ECIAEncision8.20%LENSPresbia16.42%NVIVInVivo Therapeutics13.78%Insider OwnershipCompanyInsider OwnershipAPOPCellect BiotechnologyN/ACYTXCytori Therapeutics0.66%ECIAEncision40.87%LENSPresbia74.20%NVIVInVivo Therapeutics2.45%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPOPCellect Biotechnology2,020977,000N/ANot OptionableCYTXCytori Therapeutics3722.16 millionN/ANot OptionableECIAEncision3111.86 million7.02 millionNot OptionableLENSPresbia2417.23 millionN/ANot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableNVIV, LENS, APOP, CYTX, and ECIA HeadlinesSourceHeadlineInterview: Emmes Mindy Leffler - are video based assessments the way forward to evaluate patients at home?outsourcing-pharma.com - April 8 at 7:38 PMGut health supplements are everywhere – but which are the best ones for *you*?msn.com - March 28 at 4:18 PMDrug discovery and global player, Cresset, moves team into Boston marking major turning pointoutsourcing-pharma.com - March 12 at 7:43 PMInVivo Therapeutics Holdings Corporationcnn.com - February 15 at 12:40 AMInVivo Therapeutics Holdings Corp.wsj.com - February 14 at 2:40 PMFirm Retention Summary: InVivo Therapeutics Holdingswsj.com - February 13 at 6:29 PMInVivo Therapeutics Holdings Corp (NVIV)investing.com - February 7 at 11:49 PMBob Langer-founded device-maker declares bankruptcybizjournals.com - February 6 at 4:38 PMWhy Is InVivo Therapeutics (NVIV) Stock Up 61% Today?investorplace.com - February 6 at 9:12 AMInVivo Therapeutics Shares Plumb New Depths After Bankruptcy Filingmarketwatch.com - February 1 at 2:09 PMSpinal Cord Injury Therapeutics Market surpass $10.7 billion by 2031 - Exclusive Report by Coherent Market Insightsprnewswire.co.uk - January 31 at 12:06 PMInVivo Therapeutics Holdings: Submission Of Matters To A Vote Of Security Holderscbonds.com - January 5 at 10:04 AMInVivo Biosystems Secures New Investment to Accelerate CRISPR Innovationpharmiweb.com - January 4 at 1:33 PMInVivo Therapeutics Holdings Corp NVIVmorningstar.com - November 10 at 7:26 AMApollo, Nimbus lead bumper week for biotech financingspharmaphorum.com - September 8 at 9:41 AMAustralia’s United Malt OKs $1-B takeover offer from France’s InVivobusiness.inquirer.net - July 2 at 10:09 PMSpinal Cord Trauma Treatment Market Analysis: Examining Trends and Forecasting Revenue Growth with an estimated CAGR 6.2% from 2023-2030marketwatch.com - June 22 at 5:14 PMRing Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate Strategybenzinga.com - May 1 at 12:30 PMWhy InVivo Therapeutics Shares Are Plunging Todayfinance.yahoo.com - March 17 at 1:53 AMInVivo seeks longer-term control in Casino-Teract retail tie-upmsn.com - March 10 at 6:45 PMWhy Barnes & Noble Education Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarketmsn.com - March 10 at 6:45 PMU.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.66%msn.com - March 10 at 3:10 AMWhy JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionmsn.com - March 9 at 5:08 PMInVivo : INSPIRE 2.0 Study In Acute Spinal Cord Injury Fails To Meet Primary Endpointmarkets.businessinsider.com - March 9 at 5:08 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCellect BiotechnologyNASDAQ:APOPCellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.Cytori TherapeuticsNASDAQ:CYTXCytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.EncisionOTCMKTS:ECIAEncision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.PresbiaNASDAQ:LENSPresbia PLC is a holding company. It engages in the development and marketing of presbyopia-correcting solutions under the trademark of Presbia Flexivue Microlens. It operates through the Restoration of Clear Vision Caused by Presbyopia segment. The company was founded on February 2, 2014 and is headquartered in Dublin, Ireland.InVivo TherapeuticsNASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.